Inhibrx director Jon Kayyem buys $567,580 in company stock By Investing.com
➡️ Did someone forward you this email? If you would like to receive this information directly, every morning before the markets open in New York, sign up here. ONE BIG THING OpenAI failed to disclose out-of-control
